Corporate Reputation

J&J marketing triggers $2.2B payout

J&J marketing triggers $2.2B payout

By

The company will shell out $2.2 billion over allegations of marketing misconduct for Risperdal, Invega and Natrecor.

Merck's Heller on how to get more women into the C-suite

Merck's Heller on how to get more women into the C-suite

By

Bridgette Heller, Merck EVP and president of its consumer care division, adjured life-sci managers to enable women to unleash the full power of their knowledge and ideas to drive growth in the business.

J&J consolidates, rebrands Ethicon units

J&J consolidates, rebrands Ethicon units

By

Driven by consolidation in the healthcare industry, J&J is reuniting Ethicon, Inc. and Ethicon Endo-Surgery to present surgeons and health systems with a single face.

Komen announces executive shakeup

Komen announces executive shakeup

By

The non-profit announced Thursday that it is on the hunt for a new president and two new board members, and that its beleaguered CEO will step down.

Shake-up at top for J&J, as Weldon exits CEO post

By

The most recent Johnson & Johnson recall may officially be CEO William Weldon's last. Alex Gorsky will become CEO as of April 26, the company said, and Weldon will stay on as chairman of the board of directors.

Poll shows J&J rep is dented, not destroyed

By

Despite recalls, a settlement over allegations of Medicare Fraud and illicit marketing of off-label drug use, a poll by research group Harris Interactive indicates that Johnson & Johnson's corporate reputation is dented, but intact.

Komen, caught up in the culture wars, nurses damaged brand

Komen, caught up in the culture wars, nurses damaged brand

By

Cowed by a fierce and lighting-quick backlash fueled by angry Tweets and Facebook posts, The Susan G. Komen for the Cure Foundation is backpedaling, but is it too late to reverse the reputation damage?

Merck wraps up Vioxx litigation with feds, states: $1b in fines, new CIA

Merck wraps up Vioxx litigation with feds, states: $1b in fines, new CIA

By

Seven years after the biggest drug safety scandal since thalidomide was found to cause birth defects, Merck and the Justice Department announced a nearly $1 billion settlement of litigation over Vioxx, the Cox-2 pain drug found to cause strokes and heart attacks.

Bayer beefs up Ob/Gyn sales calls

Bayer beefs up Ob/Gyn sales calls

By

Pfizer has usurped Merck as the most admired drug company among obstetricians and gynecologists, according to SDI's Pharmaceutical Company Image 2011 study, while Bayer increased its sales presence in that specialty significantly.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.